Hair Loss News

Navigation

Hair Loss News Archives


April 2006


Mylan Cleared to Market Proscar Generic

 

Mylan Receives FDA Clearance for Generic Version of Merck's Proscar Prostate-Cancer Drug

Generic-pharmaceutical company Mylan Laboratories Inc. said Tuesday the U.S. Food and Drug Administration granted tentative approval for the company's generic version of Merck & Co.'s Proscar.

Mylan applied to the FDA to market finasteride tablets as a generic version of Proscar, which treats prostate cancer and male-pattern baldness.

Mylan cited IMS Health that measured Proscar's 2005 U.S. sales at $390 million.

Mylan Laboratories shares rose a penny to $22.13 while Merck shares rose 25 cents to $34.05 in morning trading on the New York Stock Exchange.